報價延遲最少15分鐘:2025/09/04 05:14 EDT
盤前時段
|
||||
|
1.67 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.67
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-12.12/-3.02
|
|
企業價值
12.18M
|
| 資產負債 |
|
每股賬面淨值
2.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 05:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
